<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381118</url>
  </required_header>
  <id_info>
    <org_study_id>31/17-n</org_study_id>
    <nct_id>NCT03381118</nct_id>
  </id_info>
  <brief_title>Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients</brief_title>
  <official_title>A Randomized Study of Haploidentical Lymphocytes With Nivolumab and Intermediate Dose Cytarabine Versus Nivolumab and Intermediate Dose Cytarabine as Consolidation Treatment in Older Adults With Acute Myeloid Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II trial to compare the efficacy and safety of nivolumab and intermediate dose
      cytarabine with or without haploidentical lymphocyte infusion. To identify the role of
      haploidentical lymphocytes in the treatment of acute myeloid leukemia in older adults. The
      patients will be stratified based on the remission number (first or second)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>DFS will be assessed with Kaplan-Meier method from the date of last remission before randomization until the date of relapse or the date of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>OS will be assessed with Kaplan-Meier method from the date of last remission before randomization until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft-versus-host disease</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Incidence of acute GVHD, grades I-IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Toxicity parameters based on NCI CTCAE 4.03 grades: hematological toxicity (CBC), hepatotoxicity (liver function tests), nephrotoxicity (creatinine), neurotoxicity (attending physician assessment), fatigue (attending physician assessment), rash (attending physician assessment), colitis (attending physician assessment), pneumonitis (attending physician assessment), autoimmune disorders (level of hormones, presence of autoimmune antibodies, attending physician assessment).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Ara-C+HaploLymphocyte+Nivo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with nivolumab, intermediate dose cytarabine and haploidentical lymphocyte infusion:
[Cytarabine 500-1000 mg/m2 bid D-4, -3, -2 + G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells infusion D0
+ Nivolumab 40 mg D+5] х 2-3 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ara-C+ Nivo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with nivolumab and intermediate dose cytarabine:
[Cytarabine 500-1000 mg/m2 bid D+1, +2, +3 + Nivolumab 40 mg D+1] х 2-3 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2</description>
    <arm_group_label>Ara-C+HaploLymphocyte+Nivo</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 40 mg IV infusion on D+5</description>
    <arm_group_label>Ara-C+HaploLymphocyte+Nivo</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3</description>
    <arm_group_label>Ara-C+ Nivo</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 40 mg IV infusion on D+1</description>
    <arm_group_label>Ara-C+ Nivo</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G-CSF mobilized HLA-haploidentical donor PBSC</intervention_name>
    <description>G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0</description>
    <arm_group_label>Ara-C+HaploLymphocyte+Nivo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of acute myeloid leukemia with the confirmed first or second
             complete remission

          -  ≥ 55 years of age

          -  Not candidates for allogeneic stem cell transplantation as decided by the panel of
             hematologists at the transplant center

          -  Patients with a HLA-haploidentical donor who should be able to provide informed
             consent for peripheral blood apheresis

          -  No severe concurrent illness that limits life expectancy to less than 2 years

        Exclusion Criteria:

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Karnofsky index &lt;70%

          -  Acute promyelocytic leukemia

          -  Other tumor requiring treatment at the time of enrollment

          -  Active or prior documented autoimmune disease requiring systemic treatment

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boris Afanasyev, MD, Prof.</last_name>
    <phone>+78122334551</phone>
    <email>coordinatorbmt@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Smirnova, PhD</last_name>
    <phone>+7-921-370-74-35</phone>
    <email>dr.annasmirnova@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boris V Afanasyev, MD, Prof.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Smirnova, PhD</last_name>
      <phone>+7-921-370-74-35</phone>
      <email>dr.annasmirnova@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sergey Bondarenko, PhD</last_name>
      <phone>+7-921-994-35-70</phone>
      <email>dr.sergeybondarenko@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Olesya Smykova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Petersburg State Pavlov Medical University</investigator_affiliation>
    <investigator_full_name>Ivan S Moiseev</investigator_full_name>
    <investigator_title>Vice-director for science of R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

